

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1 of 1

Complete if Known

Application Number	10/662594
Filing Date	9/15/2003
First Named Inventor	Arnold
Art Unit	
Examiner Name	

Attorney Docket Number LPJ6OXO

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	MARSH, BRODIE, GARRETT, TSAI-MORRIS & BRODIE, Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives, J Med Chem 1985 Jun;28(6):788-95	
	2	BOOTH, Effects of the aromatization inhibitor androst-4-ene-3,6,17-trione on sexual differentiation induced by testosterone in the neonatally castrated rat, J Endocrinol. 1978	
	3	SCIARRA & TOSCANO, Role of estrogens in human benign prostatic hyperplasia, Arch Androl. 2000 May-Jun;44(3):213-20	
	4	VERMEULEN, KAUFMAN, GOEMAERE & VAN POTTELBERG, Estradiol in elderly men, Aging Male. 2002 Jun;5(2):98-102	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*9/15/03*

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/662594
(Use as many sheets as necessary)				Filing Date	9-5-03
				First Named Inventor	Arnold
				Art Unit	1614
				Examiner Name	SPIVACK
Sheet	1	of	1	Attorney Docket Number	LPJ6OXO

*Applicant's*

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	MARSH, BRODIE, GARRETT, TSAI-MORRIS & BRODIE, Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives, J Med Chem 1985 Jun;28(6):788-95		T <sup>2</sup>
	2	BOOTH, Effects of the aromatization inhibitor androst-4-ene-3,6,17-trione on sexual differentiation induced by testosterone in the neonatally castrated rat, J Endocrinol. 1978		
	3	SCIARRA & TOSCANO, Role of estrogens in human benign prostatic hyperplasia, Arch Androl. 2000 May-Jun;44(3):213-20		
	4	VERMEULEN, KAUFMAN, GOEMAERE & VAN POTTELBERG, Estradiol in elderly men, Aging Male. 2002 Jun;5(2):98-102		
PS	5	TAN et al., De novo biosynthesis of 6 beta-hydroperoxyandrostenedione in human placental microsomes, Biochem Biophys Res Commun. 1984 Feb 14;118(3):805-13		

Examiner Signature	<i>P. Spivack</i>	Date Considered	12/30/05
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.